Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
Oncologists to present latest research findings at ASCO annual meeting

Oncologists to present latest research findings at ASCO annual meeting

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology annual meeting, June 3-7 in Chicago. [More]
Axumin approved for use in PET scans in patients with recurrent prostate cancer

Axumin approved for use in PET scans in patients with recurrent prostate cancer

The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment. [More]
Healthy lifestyle may help women reduce chances of developing breast cancer

Healthy lifestyle may help women reduce chances of developing breast cancer

Women with a high risk of developing breast cancer based on family history and genetic risk can still reduce the chance they will develop the disease in their lifetimes by following a healthy lifestyle, new research led by the Johns Hopkins Bloomberg School of Public Health suggests. [More]
Metabolic characteristics of CRPC may open new avenues for treatment

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition. [More]
Lancet study links worldwide economic crisis to increased cancer mortality

Lancet study links worldwide economic crisis to increased cancer mortality

Unemployment and reduced public-sector health spending following the 2008 global economic crisis were associated with increased cancer mortality, according to a new study published in The Lancet. [More]
Mindfulness intervention provides greater resilience, less anxiety in prostate cancer patients

Mindfulness intervention provides greater resilience, less anxiety in prostate cancer patients

Men with prostate cancer who are under close medical surveillance reported significantly greater resilience and less anxiety over time after receiving an intervention of mindfulness meditation, according to a recently published pilot study from the Northwestern University Feinberg School of Medicine. [More]
Nutrition, safety tips for grilling season

Nutrition, safety tips for grilling season

Cooking meat, including beef, pork, fish, or poultry, with high-temperature methods such as pan frying or grilling directly over an open flame can increase exposure to chemicals that can cause changes in DNA that may increase the risk of cancer, according to the National Cancer Institute. [More]
Mitoxantrone for MS linked to colorectal cancer risk

Mitoxantrone for MS linked to colorectal cancer risk

Treatment with mitoxantrone for multiple sclerosis carries only a mildly increased risk of malignancy overall, but the risk of colorectal cancer and leukaemia is heightened, researchers have found. [More]
Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

The lab of Rice University synthetic organic chemist K.C. Nicolaou has reported the streamlined total synthesis of delta12-prostaglandin J3, a molecule previously claimed to kill leukemic cancer cells. [More]
Physical exercise may be as effective as drugs for treating prostate cancer patients

Physical exercise may be as effective as drugs for treating prostate cancer patients

At age 70, Alfred Roberts plays hockey twice a week. Nothing special, right? Except that for three years he has had advanced prostate cancer, which has spread to his bones. "I've always been active. Hockey keeps me in shape and keeps my mind off things. I've got friends that have played until age 80, and my goal is to beat them!" said the veteran stick handler. [More]
Raman spectroscopic technique helps detect unique cellular changes that occur following radiation

Raman spectroscopic technique helps detect unique cellular changes that occur following radiation

The Irving K Barber School of Arts and Sciences at the University of British Columbia, Canada, hosts a multidisciplinary group of physics, engineering and radiation oncology scientists. [More]
Could whole-mount scanning of breast tissue lead to better clinical outcomes? An interview with Dr Martin Yaffe

Could whole-mount scanning of breast tissue lead to better clinical outcomes? An interview with Dr Martin Yaffe

We actually normally refer to this as whole-specimen imaging of breast tissue. What we mean is that when tissue is removed from the breast, which could be in the form of a lumpectomy – a breast-conserving surgery – or a mastectomy, the piece of tissue removed is relatively large. [More]
Cornell researchers develop nanoparticle-based drug delivery mechanism for combination cancer therapy

Cornell researchers develop nanoparticle-based drug delivery mechanism for combination cancer therapy

A team of researchers from Cornell University in Ithaca, New York demonstrated a drug delivery mechanism that utilizes two independent vehicles, allowing for delivery of chemically and physically dis-tinct agents. [More]
Robotic-assisted radical prostatectomy may reduce risk of blood loss, prolonged hospital stays in obese men

Robotic-assisted radical prostatectomy may reduce risk of blood loss, prolonged hospital stays in obese men

In obese prostate cancer patients, robotic-assisted surgery to remove the prostate reduces the risk of blood loss and prolonged hospital stays, a Loyola Medicine study has found. [More]
Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility of tumor cell-free DNA as a predictor of therapeutic response to immunotherapy after the first cycle of treatment in eight different types of cancer. [More]
AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

Prostate cancer is the second leading cause of mortality among American men with the highest incidence rate of all cancers reported in the U.S. Male sex hormones testosterone (T) and 5α-dihydrotestosterone (5α-DHT) promote prostate cancer progression. [More]
Clinicians perform UK’s first MRI-guided focused ultrasound treatment for prostate cancer

Clinicians perform UK’s first MRI-guided focused ultrasound treatment for prostate cancer

INSIGHTEC congratulates the medical team at Imperial College Healthcare NHS Trust for performing the first MR-guided focused ultrasound treatment in the United Kingdom for prostate cancer. [More]
Ipsen partners with IMCB to advance understanding and research of Botulinum Neurotoxin Biology

Ipsen partners with IMCB to advance understanding and research of Botulinum Neurotoxin Biology

Ipsen S.A., a global specialty-driven pharmaceutical company, and the Institute of Molecular and Cell Biology (IMCB), a research institute under the aegis of the Agency for Science, Technology and Research (A*STAR), Singapore, today announced the signature of a research partnership to study the intracellular trafficking of botulinum neurotoxins (BoNTs) within neurons. [More]
Genomic cfDNA profiling feasible in metastatic CRPC

Genomic cfDNA profiling feasible in metastatic CRPC

Comprehensive genomic profiling of cell-free DNA can provide clinically useful information in men with castration-resistant prostate cancer treated with enzalutamide, research indicates. [More]
Vessel-sparing radiation, better understanding of prostate anatomy can improve quality of life

Vessel-sparing radiation, better understanding of prostate anatomy can improve quality of life

Remember the game Operation? You need to carefully remove the body part without nicking the sides or the buzzer will sound. [More]
Advertisement